FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy
Executive Summary
An FDA analysis of Lilly's Xigris Phase III efficacy data suggests that the APACHE II sepsis scale may be a useful guide for identifying candidates for therapy.
You may also be interested in...
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
The APACHE II sepsis score is the most appropriate tool to estimate the likelihood of a Xigris benefit in a particular patient, labeling for Lilly's biologic states
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
The APACHE II sepsis score is the most appropriate tool to estimate the likelihood of a Xigris benefit in a particular patient, labeling for Lilly's biologic states
Lilly Xigris Indication For Low-Risk Sepsis Could Require Large Study
Lilly's Xigris efficacy assessment in low-risk sepsis patients would require a large trial population, FDA's Anti-Infective Drugs Advisory Committee suggested Oct. 16.